



Up-to-date Questions and Answers from authentic resources to improve knowledge and pass the exam at very first attempt. ---- Guaranteed.



SOCRA-CCRP MCQs
SOCRA-CCRP TestPrep
SOCRA-CCRP Study Guide
SOCRA-CCRP Practice Test
SOCRA-CCRP Exam Questions



killexams.com

Nursing

SOCRA-CCRP

SOCRA Certified Clinical Research Professional

ORDER FULL VERSION

<https://killexams.com/pass4sure/exam-detail/SOCRA-CCRP>



Question: 1

According to the Declaration of Helsinki, which of the following statements is true regarding the participation of vulnerable populations in research?

- A. Vulnerable populations should not participate in research to avoid potential harm.
- B. The participation of vulnerable populations should be limited to non-invasive studies only.
- C. Additional safeguards should be provided to protect the rights and welfare of vulnerable populations.
- D. Vulnerable populations can participate in research without any additional considerations.

Answer: C

Explanation: According to the Declaration of Helsinki, additional safeguards should be provided to protect the rights and welfare of vulnerable populations participating in research. Vulnerable populations include individuals who may have limited autonomy, diminished decision-making capacity, or are at a higher risk of coercion or exploitation. Examples of vulnerable populations include children, prisoners, pregnant women, and individuals with mental impairments. The Declaration of Helsinki recognizes the importance of ensuring their protection and requires researchers to implement additional measures to safeguard their rights and well-being during the research process.

Question: 2

Which of the following regulations governs the protection of human subjects in non-FDA-regulated research conducted in the United States?

- A. 21 U.S. Code of Federal Regulations – Part 50
- B. 21 U.S. Code of Federal Regulations – Part 56

- C. 45 U.S. Code of Federal Regulations - Part 46
- D. ICH GCP Guideline for Good Clinical Practice E6(R2)

Answer: C

Explanation: The protection of human subjects in non-FDA-regulated research conducted in the United States is governed by 45 U.S. Code of Federal Regulations - Part 46. This regulation, often referred to as the Common Rule, applies to research involving human subjects conducted or supported by federal departments and agencies. It establishes the ethical standards and requirements for the protection of human subjects, including informed consent, institutional review boards (IRBs), and the minimization of risks. 21 U.S. Code of Federal Regulations – Part 50 and Part 56 primarily pertain to FDA-regulated research, while the ICH GCP Guideline for Good Clinical Practice E6(R2) provides international standards for clinical trials.

Question: 3

Which document provided the ethical framework for the protection of human subjects in the United States?

- A. The Nuremberg Code
- B. The Belmont Report
- C. The Declaration of Helsinki
- D. 21 U.S. Code of Federal Regulations – Part 50

Answer: B

Explanation: The Belmont Report, published in 1979, provided the ethical framework for the protection of human subjects in the United States. It was prepared by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The report outlines three core principles: respect for persons, beneficence, and justice. These principles form the basis for

the ethical conduct of research involving human subjects in the United States.

Question: 4

Which international document provides guidelines for medical research involving human subjects?

- A. The Nuremberg Code
- B. The Belmont Report
- C. The Declaration of Helsinki
- D. ICH GCP Guideline for Good Clinical Practice E6(R2)

Answer: C

Explanation: The Declaration of Helsinki is an international ethical guideline for medical research involving human subjects. It was first adopted in 1964 by the World Medical Association and has been revised several times since then. The Declaration of Helsinki provides guidance on ethical principles, responsibilities of researchers, informed consent, participant protection, and other aspects related to the conduct of medical research. It serves as a globally recognized reference for ensuring the ethical conduct of research involving human subjects.

Question: 5

Which set of regulations governs the conduct of clinical trials in the United States?

- A. 21 U.S. Code of Federal Regulations – Part 11
- B. 21 U.S. Code of Federal Regulations – Part 312
- C. 45 U.S. Code of Federal Regulations - Part 46
- D. 45 U.S. Code of Federal Regulations - Part 50

Answer: B

Explanation: Clinical trials in the United States are governed by the 21 U.S. Code of Federal Regulations – Part 312. This regulation sets forth the requirements for the investigational new drug application (IND) process, including the submission of clinical trial protocols, informed consent, monitoring, reporting of adverse events, and other aspects related to the conduct of clinical trials involving investigational drugs.

Question: 6

Which of the following is a requirement outlined in 21 U.S. Code of Federal Regulations – Part 312?

- A. Reporting of serious adverse events to the sponsor
- B. Obtaining informed consent from research subjects
- C. Establishing an institutional review board (IRB)
- D. Conducting regular monitoring visits at investigational sites

Answer: A

Explanation: 21 U.S. Code of Federal Regulations – Part 312 outlines the requirements for Investigational New Drug (IND) applications in the United States. One of the requirements stated in this regulation is the reporting of serious adverse events to the sponsor. Sponsors are responsible for promptly reporting any serious adverse events that occur in connection with the use of the investigational drug to the appropriate regulatory authorities, such as the FDA. Obtaining informed consent from research subjects is covered under 21 U.S. Code of Federal Regulations – Part 50, establishing an institutional review board (IRB) is addressed in Part 56, and conducting regular monitoring visits at investigational sites is a practice associated with Good Clinical Practice (GCP) guidelines.

Question: 7

According to ICH Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (E2A), which of the following is considered an expedited reporting event?

- A. Any adverse event occurring during the course of the clinical trial
- B. Serious adverse events that are unexpected and related to the investigational product
- C. Non-serious adverse events that are expected and consistent with the product's labeling
- D. Adverse events that occur in a control group but not in the treatment group

Answer: B

Explanation: According to ICH Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (E2A), expedited reporting events refer to serious adverse events that are unexpected and related to the investigational product. These events require immediate reporting to regulatory authorities and ethics committees. Expedited reporting ensures that potential safety concerns are promptly communicated and appropriate actions are taken to protect the well-being of study participants.

Question: 8

According to the Nuremberg Code, which of the following is a fundamental ethical principle for human experimentation?

- A. Voluntary informed consent of the subject
- B. Maximizing benefits for society
- C. Conducting experiments without regard to potential risks
- D. Excluding vulnerable populations from participation

Answer: A

Explanation: The Nuremberg Code, formulated as a result of the Nuremberg trials after World War II, established ethical principles for human experimentation. One of its fundamental principles is the requirement of voluntary informed consent from the research subject. This means that individuals must be fully informed about the nature, purpose, risks, and benefits of the research study before they can voluntarily agree to participate. Informed consent ensures respect for individual autonomy and protects the rights and welfare of research subjects.

Question: 9

According to ICH GCP Guideline for Good Clinical Practice E6(R2), which of the following is a key responsibility of the sponsor in a clinical trial?

- A. Providing medical care to study participants
- B. Conducting the statistical analysis of study data
- C. Ensuring the trial is conducted in compliance with the protocol and applicable regulations
- D. Interpreting the study results and drawing conclusions

Answer: C

Explanation: According to the ICH GCP Guideline for Good Clinical Practice E6(R2), the sponsor in a clinical trial has the key responsibility of ensuring that the trial is conducted in compliance with the protocol and applicable regulations. The sponsor is responsible for designing the study, obtaining regulatory approvals, providing investigational products, monitoring the trial, ensuring data quality, and taking overall accountability for the conduct of the trial. Compliance with the protocol and applicable regulations is crucial to protect the rights, safety, and well-being.

Question: 10

According to ICH GCP Guideline for Good Clinical Practice E6(R2), which of the following is a key responsibility of the investigator?

- A. Reviewing and approving the study protocol
- B. Monitoring the study data for quality and accuracy
- C. Conducting statistical analysis of the study results
- D. Preparing the Investigational New Drug (IND) application

Answer: B

Explanation: According to ICH GCP Guideline for Good Clinical Practice E6(R2), a key responsibility of the investigator is to monitor the study data for quality and accuracy. The investigator is responsible for ensuring that the data collected during the clinical trial is complete, accurate, and verifiable. This includes conducting regular monitoring visits at the investigational site to review and verify the source documents, case report forms, and other study-related records. Reviewing and approving the study protocol is typically the responsibility of the sponsor and/or the institutional review board (IRB). Statistical analysis of the study results is usually performed by a biostatistician, and preparing the Investigational New Drug (IND) application is the responsibility of the sponsor.

Question: 11

According to the Belmont Report, which principle emphasizes the fair distribution of the benefits and burdens of research?

- A. Respect for persons
- B. Beneficence
- C. Justice

D. Autonomy

Answer: C

Explanation: According to the Belmont Report, the principle of justice emphasizes the fair distribution of the benefits and burdens of research. Justice requires that the selection of research participants is equitable, without any unjustifiable exclusions or preferences. It also highlights the importance of avoiding exploitation and ensuring that the potential benefits of research are shared fairly among the population under study. This principle safeguards against discrimination and promotes fairness in the conduct of research.

Question: 12

Which document provides guidelines for the management of safety data in clinical trials?

- A. The Nuremberg Code
- B. The Declaration of Helsinki
- C. ICH GCP Guideline for Good Clinical Practice E6(R2)
- D. ICH Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (E2A)

Answer: D

Explanation: ICH Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (E2A) provides guidelines for the management of safety data in clinical trials. This document outlines definitions and standards for the collection, processing, analysis, and reporting of safety data. It emphasizes the importance of timely and accurate reporting of adverse events, ensuring that the safety of study participants is a top priority throughout the course of the clinical trial.

Question: 13

Which set of regulations provides guidelines for the protection of human subjects in non-exempt research conducted or supported by the U.S. Department of Health and Human Services (HHS)?

- A. 21 U.S. Code of Federal Regulations – Part 11
- B. 21 U.S. Code of Federal Regulations – Part 46
- C. 45 U.S. Code of Federal Regulations - Part 50
- D. 45 U.S. Code of Federal Regulations - Part 312

Answer: B

Explanation: The protection of human subjects in non-exempt research conducted or supported by the U.S. Department of Health and Human Services (HHS) is governed by the 45 U.S. Code of Federal Regulations - Part 46. This regulation, also known as the Common Rule, establishes the ethical standards for the protection of human subjects in research. It applies to a wide range of research activities, including biomedical and behavioral studies, and covers both federally funded and non-federally funded research.

Question: 14

Which of the following is a requirement stated in 21 U.S. Code of Federal Regulations – Part 56?

- A. Obtaining informed consent from research subjects
- B. Reporting of serious adverse events to the sponsor
- C. Establishing an institutional review board (IRB)
- D. Conducting regular monitoring visits at investigational sites

Answer: C

Explanation: 21 U.S. Code of Federal Regulations – Part 56 outlines the requirements for institutional review boards (IRBs) in the United States. One of the key requirements stated in this regulation is the establishment of an IRB. An IRB is an independent committee responsible for reviewing, approving, and monitoring research involving human subjects to ensure the protection of their rights and welfare. Obtaining informed consent from research subjects is covered under 21 U.S. Code of Federal Regulations – Part 50, reporting of serious adverse events to the sponsor is addressed in Part 312, and conducting regular monitoring visits at investigational sites is a practice associated with Good Clinical Practice (GCP) guidelines.

Question: 15

According to ICH Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (E2A), which of the following is an example of a serious adverse event (SAE)?

- A. Mild headache lasting for 30 minutes
- B. Slight skin irritation at the site of application
- C. Moderate nausea and vomiting after taking the study medication
- D. Life-threatening allergic reaction requiring hospitalization

Answer: D

Explanation: According to ICH Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (E2A), a serious adverse event (SAE) is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. Among the options provided, a life-threatening allergic reaction requiring hospitalization is the only example that meets the criteria for an SAE. Mild headache, slight skin irritation, and moderate nausea

and vomiting, while adverse events, do not meet the criteria for seriousness as defined by E2A.



Killexams.com is a leading online platform specializing in high-quality certification exam preparation. Offering a robust suite of tools, including MCQs, practice tests, and advanced test engines, Killexams.com empowers candidates to excel in their certification exams. Discover the key features that make Killexams.com the go-to choice for exam success.



Exam Questions:

Killexams.com provides exam questions that are experienced in test centers. These questions are updated regularly to ensure they are up-to-date and relevant to the latest exam syllabus. By studying these questions, candidates can familiarize themselves with the content and format of the real exam.

Exam MCQs:

Killexams.com offers exam MCQs in PDF format. These questions contain a comprehensive collection of questions and answers that cover the exam topics. By using these MCQs, candidate can enhance their knowledge and improve their chances of success in the certification exam.

Practice Test:

Killexams.com provides practice test through their desktop test engine and online test engine. These practice tests simulate the real exam environment and help candidates assess their readiness for the actual exam. The practice test cover a wide range of questions and enable candidates to identify their strengths and weaknesses.

Guaranteed Success:

Killexams.com offers a success guarantee with the exam MCQs. Killexams claim that by using this materials, candidates will pass their exams on the first attempt or they will get refund for the purchase price. This guarantee provides assurance and confidence to individuals preparing for certification exam.

Updated Contents:

Killexams.com regularly updates its question bank of MCQs to ensure that they are current and reflect the latest changes in the exam syllabus. This helps candidates stay up-to-date with the exam content and increases their chances of success.